For women with a strong family history of ovarian cancer or certain inherited genetic changes, understanding and managing ovarian cancer risk can become an important part of long-term healthcare.Ovarian cancer can be challenging to identify at an early stage because symptoms may initially be subtle and can overlap with symptoms caused by much more common conditions.
There is currently no routine population-wide ovarian cancer screening programme in the UK. However, the approach may be different for certain people who have a substantially increased inherited risk of ovarian cancer.
For selected people at increased inherited risk who choose to delay or not undergo recommended risk-reducing surgery, specialist ovarian cancer surveillance may be considered.
One approach involves serial CA125 blood tests interpreted using the Risk of Ovarian Cancer Algorithm (ROCA). Rather than relying solely on a single CA125 result, ROCA considers how CA125 levels change over time.
This article explains how the ROCA Test works, why tracking CA125 over time can provide additional information, who may be considered for surveillance and the important limitations of ovarian cancer surveillance.
Understanding Ovarian Cancer Risk in High-Risk Women
Some people have a higher lifetime risk of ovarian cancer because of inherited genetic factors or a significant family history of ovarian and related cancers.
Which Genetic Changes Can Increase Ovarian Cancer Risk?
Inherited pathogenic variants associated with an increased ovarian cancer risk include
BRCA1 and BRCA2, together with other genes such as
RAD51C, RAD51D, BRIP1 and PALB2.
A significant family history of ovarian or breast cancer may also indicate that formal genetic risk assessment should be considered, even when a genetic variant has not previously been identified within the family.
Why Is Specialist Risk Assessment Important?
An individual's ovarian cancer risk cannot be determined from family history or a single blood test alone.
Factors that may influence risk and management include:
- Age
- Family history
- Genetic findings
- Previous medical history
- Reproductive and fertility plans
- Menopausal status
- Previous surgery
People concerned about inherited ovarian cancer risk should discuss their circumstances with an appropriately qualified healthcare professional, genetics service or specialist gynaecology team.
What Is the ROCA Test?
ROCA stands for
Risk of Ovarian Cancer Algorithm.
It is a statistical approach that analyses serial CA125 measurements rather than relying solely on whether one CA125 result is above a fixed threshold.
What Is a CA125 Blood Test?
CA125, or cancer antigen 125, is a protein that can be measured through a blood test.
CA125 may be elevated in some people with ovarian cancer, which is why the marker is commonly associated with ovarian cancer investigation and surveillance.
However, CA125 is not specific to ovarian cancer.
Levels can change for several non-cancerous reasons. Consequently:
- A raised CA125 result does not by itself diagnose ovarian cancer.
- A CA125 result within the conventional reference range does not completely exclude ovarian cancer.
- Results need to be interpreted in the context of the person's clinical circumstances.
How Is ROCA Different From a Single CA125 Test?
A single CA125 blood test provides a snapshot of the CA125 concentration at one point in time.
ROCA takes a different approach. It evaluates serial CA125 measurements and assesses how an individual's results change over time.
Rather than asking only:
“Is this CA125 result above a particular threshold?”
ROCA also considers:
“How is this person's CA125 changing compared with their previous measurements?”
This provides a more individualised way of interpreting a sequence of CA125 results.
How Does the ROCA Test Work?
The principle behind ROCA can be thought of as
following a pattern rather than looking at a single picture.
Step 1 – CA125 Is Measured
A blood sample is collected and the CA125 concentration is measured.
Step 2 – Results Are Compared Over Time
Previous CA125 measurements provide information about how an individual's CA125 has behaved over time and help establish their longitudinal pattern.
Step 3 – The Pattern Is Analysed
The algorithm evaluates changes within the sequence of CA125 results rather than interpreting the latest result completely in isolation.
Step 4 – Appropriate Follow-Up Is Determined
Depending on the result and the clinical surveillance pathway, management may involve continued surveillance, an earlier repeat CA125 measurement or further clinical investigation.
Further Assessment May Include
- Repeat CA125 blood testing
- Clinical review
- Transvaginal ultrasound
- Specialist gynaecological assessment
- Other clinically appropriate investigations
An altered or concerning ROCA result is not a diagnosis of ovarian cancer. It indicates that the pattern may require further assessment.
Why Does Tracking CA125 Over Time Matter?
CA125 concentrations naturally vary between individuals.
This means that applying the same single threshold to every person does not necessarily capture all the information available from their previous measurements.
Personal Baseline Versus a Fixed Threshold
An individual may have CA125 measurements that remain relatively stable over time.
Previous measurements can therefore provide a personal pattern against which later results can be assessed.
A significant upward trend may warrant further assessment even when interpretation based solely on one measurement might be different.
What Is Longitudinal CA125 Testing?
Longitudinal CA125 testing means assessing a sequence of CA125 measurements over time rather than treating every blood result as an isolated event.
This longitudinal approach forms the basis of ROCA and is particularly relevant to specialist surveillance programmes for selected people with recognised inherited ovarian cancer risk.
What Does NICE Say About ROCA and Ovarian Cancer Surveillance?
The National Institute for Health and Care Excellence (NICE) guideline
NG241 – Ovarian cancer: identifying and managing familial and genetic risk provides recommendations for people with increased inherited ovarian cancer risk.
Who May Be Considered for Surveillance?
NICE states that a familial ovarian cancer multidisciplinary team may consider surveillance for certain people who choose to delay or not undergo recommended risk-reducing surgery.
This includes people:
- Over 35 years with a BRCA1 pathogenic variant
- Over 40 years with a BRCA2 pathogenic variant
- Over 45 years with a RAD51C, RAD51D, BRIP1 or PALB2 pathogenic variant
How Often Is CA125 Tested?
For selected high-risk groups covered by the NICE surveillance pathway, NICE recommends
serial CA125 longitudinal testing every four months using an algorithm with demonstrated accuracy, such as ROCA.
The familial ovarian cancer multidisciplinary team should coordinate, interpret and audit the surveillance programme.
Does Surveillance Reduce the Risk of Developing Ovarian Cancer?
No. Ovarian cancer surveillance does not reduce the underlying risk of developing ovarian cancer.NICE emphasises that surveillance should not be considered an alternative to recommended risk-reducing surgery.
This distinction is extremely important when considering the potential benefits and limitations of ROCA surveillance.
When Might ROCA Become Part of an Ovarian Cancer Surveillance Plan?
ROCA is
not intended as a routine ovarian cancer screening test for everyone.
Its role is more specific and may be relevant within specialist surveillance for people with recognised inherited ovarian cancer risk.
Strong Family History of Ovarian or Breast Cancer
Several close relatives affected by ovarian or breast cancer, particularly at younger ages, may indicate the need for formal genetic and familial risk assessment.
BRCA1 and BRCA2 Pathogenic Variants
Pathogenic variants in
BRCA1 and BRCA2 are established hereditary cancer risk factors.
People carrying these variants should receive appropriate specialist advice about their individual risks and available risk-management options.
Other Ovarian Cancer Susceptibility Genes
Inherited ovarian cancer risk is not limited to BRCA1 and BRCA2.
Other pathogenic variants recognised within NICE guidance include RAD51C, RAD51D, BRIP1 and PALB2.
ROCA Surveillance Versus Risk-Reducing Surgery
Understanding the difference between
surveillance and
risk reduction is essential.
What Does Ovarian Cancer Surveillance Do?
Surveillance monitors for changes that could indicate the need for further investigation.
It does not prevent ovarian cancer from developing.
What Is Risk-Reducing Bilateral Salpingo-Oophorectomy?
For appropriately selected people at substantially increased inherited risk,
risk-reducing bilateral salpingo-oophorectomy involves surgical removal of both fallopian tubes and ovaries.
This is an established ovarian cancer risk-reduction strategy when clinically appropriate.
Why Does Specialist Guidance Matter?
The timing and appropriateness of risk-reducing surgery require individual specialist assessment.
Factors such as the particular genetic variant, age, fertility plans and consequences of surgical menopause need to be considered.
What Happens If a ROCA Result Raises Concern?
A ROCA result that leads to further investigation does
not mean that ovarian cancer has been diagnosed.
CA125 can change for reasons unrelated to cancer, and both false-positive and false-negative results are possible.
Possible Next Steps
Depending on the longitudinal pattern and clinical pathway, further assessment may involve:
- An earlier repeat CA125 blood test
- Review of previous CA125 measurements
- Clinical assessment
- Transvaginal ultrasound
- Referral for specialist investigation
This stepwise approach helps determine when additional investigation may be appropriate.
Can ROCA Help Detect Ovarian Cancer Earlier?
Research has investigated whether longitudinal CA125 algorithms can identify potentially concerning changes that may not be identified by strategies based solely on a single fixed CA125 threshold.
However, earlier detection and a proven reduction in deaths from ovarian cancer are not the same outcome.
What Did UKCTOCS Find?
The
UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) investigated ovarian cancer screening in a large population of postmenopausal women.
Long-term analysis did not demonstrate a statistically significant reduction in ovarian cancer mortality from the multimodal screening strategy.
Why Is High-Risk Surveillance Different?
The UKCTOCS population should not simply be considered identical to people with recognised high-risk inherited pathogenic variants.
NICE has separately evaluated evidence relating to people with familial and genetic ovarian cancer risk.
Current guidance allows consideration of longitudinal CA125 surveillance for specific higher-risk groups who delay or decline risk-reducing surgery while emphasising the limitations and uncertainties of surveillance.
Ovarian Cancer Symptoms Still Matter During Surveillance
Being enrolled in an ovarian cancer surveillance programme does not mean that symptoms should be ignored between blood tests.
Possible Ovarian Cancer Symptoms
Symptoms that may require medical assessment include persistent or frequent:
- Abdominal bloating or increased abdominal size
- Pelvic or abdominal pain
- Feeling full quickly or difficulty eating
- Urinary urgency or increased urinary frequency
Other possible symptoms can include unexplained weight loss, fatigue, changes in bowel habit or abnormal vaginal bleeding.
These symptoms are common and are frequently caused by conditions other than cancer. However, persistent, frequent or unexplained symptoms should be assessed by an appropriate healthcare professional.
Do not wait for the next scheduled ROCA or CA125 blood test if concerning or persistent symptoms develop.
Benefits and Limitations of ROCA Surveillance
Potential Benefits
ROCA surveillance may:
- Provide longitudinal assessment of CA125 results
- Consider changes relative to an individual's previous measurements
- Help identify when additional investigation may be appropriate
- Form part of specialist surveillance for selected higher-risk individuals
Important Limitations
ROCA surveillance:
- Does not prevent ovarian cancer
- Cannot definitively diagnose ovarian cancer
- Can produce false-positive results
- Can produce false-negative results
- Does not replace assessment of symptoms
- Should not be regarded as an alternative to recommended risk-reducing surgery
Making Ovarian Cancer Surveillance More Personal
There is no single ovarian cancer risk-management plan that is appropriate for every person with increased inherited risk.
Specialist discussions may consider:
- The particular genetic variant
- Estimated ovarian cancer risk
- Age
- Family history
- Previous cancer history
- Fertility and reproductive plans
- Menopausal status
- Previous surgery
- Symptoms
- Previous CA125 results
- Individual circumstances and preferences
The personalised aspect of ROCA is that previous CA125 measurements contribute to the assessment rather than every result being interpreted completely independently.
ROCA Testing and Ovarian Cancer Surveillance at Miracle Inside
For people considering a
CA125 blood test,
ROCA testing or
ovarian cancer surveillance, it is important to understand what the test can and cannot provide.
The ROCA Test uses serial CA125 measurements to assess changes over time and may form part of an appropriate surveillance pathway for selected higher-risk individuals.
Learn more about Miracle Inside's Ovarian Cancer Surveillance – ROCA Test
Testing should be undertaken within an appropriate clinical pathway. People with known or suspected inherited ovarian cancer risk should discuss their individual circumstances with a suitably qualified healthcare professional or specialist genetics or gynaecology service.
Frequently Asked Questions About the ROCA Test
What does ROCA stand for?
ROCA stands for
Risk of Ovarian Cancer Algorithm. It analyses patterns in serial CA125 measurements to support risk assessment during ovarian cancer surveillance.
Is ROCA the same as a CA125 blood test?
No. A CA125 blood test measures the concentration of CA125 in the blood. ROCA uses
serial CA125 measurements over time to analyse changes in an individual's pattern.
Can the ROCA Test diagnose ovarian cancer?
No.
ROCA cannot diagnose ovarian cancer. A concerning pattern may indicate that further clinical investigation is appropriate.
Does a raised CA125 mean I have ovarian cancer?
No. CA125 can be raised for several non-cancerous reasons. A raised CA125 result therefore requires appropriate clinical interpretation and does not by itself diagnose ovarian cancer.
Can ovarian cancer occur with a normal CA125?
Yes. A CA125 measurement within the conventional reference range does not completely exclude ovarian cancer.
How often is CA125 tested during ROCA surveillance?
For selected higher-risk groups who delay or decline risk-reducing surgery, NICE recommends
serial CA125 longitudinal testing every four months using an algorithm with demonstrated accuracy.
Who may be considered for ovarian cancer surveillance?
Under NICE guidance, surveillance may be considered by a familial ovarian cancer multidisciplinary team for defined higher-risk groups who delay or decline recommended risk-reducing surgery.
Does ROCA replace risk-reducing surgery?
No.
Ovarian cancer surveillance is not an alternative to recommended risk-reducing surgery. Surveillance does not reduce the underlying risk of developing ovarian cancer.
What happens if my ROCA result changes?
Depending on the result and clinical pathway, further assessment may include an earlier repeat CA125 test, clinical review, transvaginal ultrasound or specialist investigation.
Should I consider ROCA if ovarian cancer runs in my family?
A significant family history of ovarian or related cancers may warrant formal genetic and familial risk assessment.
Whether ROCA surveillance is appropriate depends on individual risk and should be discussed with an appropriately qualified healthcare professional or specialist service.
Final Thoughts
For people at increased inherited risk of ovarian cancer, understanding available surveillance and risk-reduction options is an important part of making informed healthcare decisions.
The ROCA Test provides an individualised approach to interpreting serial CA125 measurements by examining how CA125 changes over time rather than relying solely on one result.
Current NICE guidance recognises longitudinal CA125 surveillance using an algorithm such as ROCA for defined higher-risk groups who delay or decline risk-reducing surgery.
However, surveillance has important limitations. It does not prevent ovarian cancer, cannot provide a definitive diagnosis and should not replace recommended risk-reducing strategies.
Find Out More About the ROCA Test
Ovarian Cancer Surveillance – ROCA Test | Miracle Inside
Sources and Clinical Guidance
- NICE NG241 – Ovarian cancer: identifying and managing familial and genetic risk
- NICE Evidence Review – Methods of surveillance
- National Cancer Institute – Ovarian Cancer Screening
Medical Disclaimer
This article is provided for general educational and informational purposes and does not replace personalised medical advice, genetic counselling, diagnosis or treatment. Decisions about genetic testing, ovarian cancer surveillance and risk-reducing surgery should be made with appropriately qualified healthcare professionals.
